BONITAR 100MG TABLET

About

Bonitar 100mg Tablet contains Ibandronic acid, a potent nitrogen-containing bisphosphonate primarily used in the management of osteoporosis and hypercalcemia of malignancy. Ibandronic acid works by selectively binding to the mineral matrix of bone, particularly at sites of active bone resorption. Once incorporated into the bone, it is taken up by osteoclasts, the cells responsible for breaking down bone tissue. Inside the osteoclasts, ibandronic acid inhibits farnesyl pyrophosphate synthase, an enzyme critical for the synthesis of isoprenoid lipids essential for osteoclast function and survival.

This inhibition leads to a disruption of the osteoclast cytoskeleton and induces osteoclast apoptosis, thereby reducing bone resorption without directly affecting bone formation. The net effect is an increase in bone mineral density and a reduction in the risk of fractures, particularly in postmenopausal women with osteoporosis. It also helps to normalize elevated calcium levels in patients with cancer-related hypercalcemia.

Uses

• Postmenopausal Osteoporosis
• Prevention of Osteoporosis
• Hypercalcemia of Malignancy
• Bone Metastases in Breast Cancer

Directions For Use

Take exactly as prescribed by your doctor, usually once a month on an empty stomach with a full glass of plain water. Do not lie down for at least 60 minutes after taking the tablet.

Benefits

• Increases bone mineral density
• Reduces risk of vertebral fractures
• Convenient once-monthly dosing
• Effective in treating osteoporosis
• Helps manage hypercalcemia
• Supports bone health in cancer patients

Side Effects

• Esophageal irritation
• Dyspepsia
• Abdominal pain
• Nausea
• Diarrhea
• Headache
• Musculoskeletal pain
• Flu-like symptoms
• Fatigue
• Dizziness
• Rash
• Jaw osteonecrosis (rare)

Safety Measures

• Alcohol - Excessive alcohol intake may increase the risk of osteoporosis and could potentially exacerbate gastrointestinal side effects. Moderate consumption is generally advised.
• Pregnancy - Not recommended during pregnancy due to potential adverse effects on fetal bone development. Use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is unknown if ibandronic acid is excreted in human milk. Breastfeeding is generally not recommended due to potential risks to the infant.
• Liver - No dose adjustment is typically required in patients with hepatic impairment, as ibandronic acid is not metabolized in the liver.
• Kidney - Use with caution in patients with severe renal impairment (creatinine clearance < 30 mL/min) as accumulation may occur. Not recommended in severe cases.
• Lung - Generally, no specific precautions are needed for patients with lung conditions. However, ensure adequate hydration, especially if there's a risk of dehydration.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.